GH

As of 2026-09-10, GH scores 43out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. GH trades at $159.03, within its fair-value band.

GH scores 43 out of 100 on QNTM's five-factor model — a low-conviction reading — at 43 the factor profile is among the weaker names in the universe. Its strongest factor is momentum at 72 (strong), where price trend and relative strength are working in its favor, followed by quality at 43. The weakest is value at 21, where valuation looks stretched. Among Healthcare stocks it ranks in roughly the top 44% of the Healthcare names the model scores.

On valuation, GH is priced near the top of its recent range — the rich end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 45. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on GH, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where GH sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for GH runs $90.41–$162.96. Current price $159.03 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.